Biotech Industry Examiner

Menu
Menu
subscribe now
Search
From California to Manchester: How One Gene Therapy Is Rewriting Hunter Syndrome Care

From California to Manchester: How One Gene Therapy Is Rewriting Hunter Syndrome Care

When a three-year-old from California flies to Manchester for a

The hypertension reset: a daily aldosterone blocker meets a twice-yearly gene-silencer

The hypertension reset: a daily aldosterone blocker meets a twice-yearly gene-silencer

Madrid has put blood pressure back on the biotech map.

Epigenetic Stability Linked to Lifespan in Mammals, Research Show

Epigenetic Stability Linked to Lifespan in Mammals, Research Show

Introduction The recent study published in the journal Science Advances on

Orna Therapeutics Acquires ReNAgade Therapeutics to Enhance RNA Medicine Development

Orna Therapeutics Acquires ReNAgade Therapeutics to Enhance RNA Medicine Development

Orna Therapeutics, a Massachusetts-based biotech firm specializing in circular RNA

AstraZeneca Completes Equity Investment in Cellectis to Enhance Gene Therapy Development

AstraZeneca Completes Equity Investment in Cellectis to Enhance Gene Therapy Development

AstraZeneca has completed its planned equity investment in Cellectis, a

Innovative Breakthrough in Genomics: Profluent’s OpenCRISPR-1 Revolutionizes Human Genome Editing

Innovative Breakthrough in Genomics: Profluent’s OpenCRISPR-1 Revolutionizes Human Genome Editing

In a groundbreaking achievement, the biotechnology firm Profluent has successfully

Sanofi’s $2.2bn Dynavax deal — and the quiet power of adult vaccines

Sanofi’s $2.2bn Dynavax deal — and the quiet power of adult vaccines

The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market

The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market

Chai Discovery’s $130m bet: can “CAD for molecules” make biologics faster and cheaper?

Chai Discovery’s $130m bet: can “CAD for molecules” make biologics faster and cheaper?

From Cow-Free Dairy to Human Milk 2.0: Biotechs Race to Brew Breast Milk Proteins

From Cow-Free Dairy to Human Milk 2.0: Biotechs Race to Brew Breast Milk Proteins

When the FDA Starts Trusting Algorithms: What AIM-NASH Means for Liver Drug Trials

When the FDA Starts Trusting Algorithms: What AIM-NASH Means for Liver Drug Trials

MOST POPULAR

News

The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market
The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger
Galapagos quits cell therapy. Europe’s CGT reckoning begins.
Dermatology’s next play: bispecifics that shut down OX40L and TNF

Funding

Aging Science

The explainable aging clock regulators might actually like
Impact of Space Travel on Immune Function and Potential Countermeasures
Debate Highlights: Can Aging Be Halted or Reversed? Experts Weigh In
Epigenetic Stability Linked to Lifespan in Mammals, Research Show

Genomics

M&A & Partnerships

Sanofi’s $2.2bn Dynavax deal — and the quiet power of adult vaccines
Pfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’?
More Than a Shot: Sanofi’s Vicebio Deal Shows the Power of Platform Biotech
Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide

Biotech Stocks

Psychology

Innovative Study on Addiction by Mount Sinai and Rockefeller University

Copyright © Industry Examiner 2025 . All rights reserved.

Industry Examiner LLC 166 Geary St. STE 1500 #2640, San Francisco, CA 94108

Facebook Twitter Linkedin Link
Scroll to Top